医学
嵌合抗原受体
多发性骨髓瘤
自体干细胞移植
免疫疗法
骨髓
肿瘤科
免疫系统
单克隆抗体
癌症研究
内科学
免疫学
抗体
作者
S. Yuan,Ying Chen,Huasheng Liu
标识
DOI:10.1177/20406207241237594
摘要
Multiple myeloma (MM) is a hematological cancer characterized by abnormal proliferation of plasma cells in bone marrow. In recent years, autologous stem cell transplantation (ASCT) has become the cornerstone of MM treatment. At the same time, immunotherapy, such as monoclonal antibody therapy and chimeric antigen receptor T cell (CAR-T) has also emerged, in which CAR-T is the most attractive focus. ASCT and its myeloablative preconditioning will turn its immune microenvironment into an inhibited state, which may provide an opportunity for the expansion of CAR-T cells so as to further clear the residual lesions after ASCT and reduce the recurrence rate after ASCT. Meanwhile, the infusion of CAR-T cells can accelerate the cellular immune reconstruction after ASCT of myeloma, thereby improving the antitumor effect. In order to explore the clinic value, this article reviews the progress and prospect of ASCT combined with CAR-T therapy in the treatment of MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI